Search

The T Tauri star CVSO 30, also known as PTFO 8-8695, was studied intensively with ground-based telescopes as well as with satellites over the last decade. It showed a variable light curve with additional repeating planetary transit-like dips every ∼10.8 h. However, these dimming events changed in depth and duration since their discovery and from autumn 2018 on, they were not even present or near the predicted observing times. As reason for the detected dips and their changes within the complex light curve, e.g. a disintegrating planet, a circumstellar dust clump, stellar spots, possible multiplicity, and orbiting clouds at a Keplerian co-rotating radius were discussed and are still under debate. In this paper, we present additional optical monitoring of CVSO 30 with the meter class telescopes of the Young Exoplanet Transit Initiative in Asia and Europe over the last 7 yr and characterize CVSO 30 with the new Early Data Release 3 of the European Space Agency-Gaia mission. As a result, we describe the evolution of the dimming events in the optical wavelength range since 2014 and present explanatory approaches for the observed variabilities. We conclude that orbiting clouds of gas at a Keplerian co-rotating radius are the most promising scenario to explain most changes in CVSO 30’s light curve. © 2022 The Author(s)., This work is based on observations obtained with telescopes of the University Observatory Jena, operated by the Astrophysical Institute of the Friedrich-Schiller-Universität Jena. We thank B. Baghdasaryan, N. Belko, S. Buder, M. Dadalauri, M. Geymeier, H. Gilbert, A. Gonzalez, F. Hildebrandt, H. Keppler, O. Lux, S. Masda, P. Protte, J. Trautmann, A. Trepanowski, and S. Schlagenhauf, who have been involved in some observations of this project, obtained at the University Observatory Jena. This research was partly based on data obtained at the 1.5 m telescope of the Sierra Nevada Observatory (Spain), which is operated by the Consejo Superior de Investigaciones Científicas (CSIC) through the Instituto de Astrofísica de Andalucía. We thank J.F. Aceituno and V. Casanova for their help with the observations. This publication is partly based on observations made with ESO Telescopes at the La Silla Paranal Observatory under programme ID 090.C-0448(A). RB, RN, and MM acknowledge the support of the DFG priority programme SPP 1992 ‘Exploring the Diversity of Extrasolar Planets’ in projects NE 515/58-1 and MU 2695/27-1. We acknowledge financial support from the Spanish Agencia Estatal de Investigación of the Ministerio de Ciencia, Innovación y Universidades and the ERDF through projects PID2019-109522GB-C52 and AYA2016-79425-C3-3-P, and the Centre of Excellence ‘Severo Ochoa’ award to the Instituto de Astrofísica de Andalucía (SEV-2017-0709). We thank R. Errmann for developing and providing the photometry routine ‘AUTOMAT.PY’ and also C. Broeg for his program ‘PHOTOMETRY’. This publication makes use of data products of the SIMBAD and VizieR data bases, operated at CDS, Strasbourg, France. We also thank the Gaia Data Processing and Analysis Consortium of the ESA for processing and providing the data of the Gaia mission. We thank the MAST portal for providing the TESS photometric results and the MESA Isochrones & Stellar Tracks website for the bolometric correction tables.

BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P

Radiation Protection Dosimetry, 161 (1-4), ISSN:0144-8420, ISSN:1742-3406

Introduction: a new proton gantry dedicated to advance scanning has been build at Paul Scherrer Institute (PSI) and is under commissioning. Patient positioning is foreseen to occur directly in the treatment room with an in-room CT scanner. In addition, the gantry will be equipped with an X-ray system[for full text, please go to the a.m. URL], PTCOG 48; Meeting of the Particle Therapy Co-Operative Group